Hope Swanson, PharmD, BCPS

Clinical Pharmacy Specialist

Assistant Professor, The University of Tennessee Health Sciences Center, Department of Clinical Pharmacy and Translational Science

Board Certification

BCPS

Education

PharmD – University of South Carolina College of Pharmacy, Columbia, South Carolina

Post-Graduate Training

PGY1 Pharmacy Practice Residency - Baptist Memorial Hospital-Memphis, Memphis, Tennessee
PGY2 Oncology Pharmacy Residency – St. Jude Children’s Research Hospital, Memphis, Tennessee

Focused Area of Practice

Leukemia/Lymphoma

Honors & Awards

2020 Clinical Care Improvement Award for Clinical Pharmacy Services, St. Jude Children’s Research Hospital

St. Jude Committee Service

Antimicrobial Utilization and Improvement Committee

Pharmacy Organizations/Committee Service

American College of Clinical Pharmacy-Member
Hematology Oncology Pharmacy Association-Member
Children’s Oncology Group-Member
International Society of Oncology Pharmacy Practitioners-Member

Selected Publications

Moody J, Barker PJ, Sciasci J, Pauley JL, Bragg A, McMillan C, Triplett BM, Swanson HD. Blinatumomab infusion interruptions in pediatric patients rarely lead to readmission. Pediatr Blood Cancer. 2024; 71 (10):e31223

Gaietto A, Panetta JC, Pauley JL, Relling MV, Ribeiro R, Ehrhardt MJ, Pui CH, Inaba H, Swanson HD. Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children’s Research Hospital. Cancer Chemother Pharmacol. 2024; 93 (6): 617-625.

Hoshitsuki K, Zhou Y, Miller AM, Choi JK, Swanson HD, Bhakta NH, Jeha S, Karol SE, Ribeiro RC, Rubnitz JE, Mullighan CG, Cheng C, Yang JJ, Relling MV, Pui CH, Inaba H. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2023. Aug 5. doi: 10.1038/s41375-023-01992-z.

Purvis KN, Swanson HD, Niloy KK, Zhou Y, Panetta JC, Crews KR, Flerlage JE. Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma. Cancer Chemother Pharmacol. 2023; 92 (1):1-6.

Gruber TA, Pei D, Choi J, Cheng C, Coustan-Smith E, Campana D, Swanson HD, Pauley JL, Inaba H. Clofarabine treatment of KMT2Ar infantile patients with acute lymphoblastic leukemia in St. Jude Total Therapy Study 16. Blood Adv. 2022; 6 (24): 6131-6134.

Swanson HD, Hakim H, Hijano DR, Morton T, Cross S, Inaba H, Jeha S, Pui CH, Karol SE. Vaccines against SARS-CoV-2 are safe to administer in patients with antibodies to pegaspargase. Cancer Med 2022 Jul 15. doi: 10.1002/cam4.5011.

Lambrix AA, Swanson HD, Pauley JL, Bragg AW, Carias DC, Bourque MS, Zhou Y, Cheng C, Greene WL, Maron G. Experience using intravenous posaconazole in pediatric and young adult oncology patients. J Antimicrob Chemother. 2020; 75 (12): 3682-3687.

Panetta JC, Liu Y, Swanson HD, Karol SE, Pui CH, Inaba H, Jeha S, Relling MV. Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. Pediatr Blood Cancer. 2020 Jul;67(7):e28244. doi: 10.1002/pbc.28244. Epub 2020 Apr 23.

Swanson HD, Panetta JC, Barker PJ, Liu Y, Inaba H, Relling MV, Pui CH, Karol SE. Predicting success of desensitization after pegaspargase allergy. Blood. 2020 Jan 2;135(1):71-75.

Liu Y, Smith CA, Panetta JC, Yang W, Thompson LE, Counts JP, Molinelli AR, Pei D, Kornegay NM, Crews KR, Swanson H, Cheng C, Karol SE, Evans WE, Inaba H, Pui CH, Jeha S, Relling MV. Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. J Clin Oncol. 2019 Aug 10;37(23):2051-2061.

Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, Swanson, HD. Wolf J, Greene W. Pentamidine for prophylaxis against Pneumocystis jirovecii pneumonia in pediatric oncology patients receiving immunosuppressive chemotherapy. Antimicrob Agents Chemother. 2018; 62: e00173-18.

Scott JR, Zhou Y, Cheng C, Ward DA, Swanson HD, et al. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Pediatric Blood and Cancer. 2015; 62:1518-1522.

Last update: October 2024